Patent Term Application for KEBILIDI® (eladocagene exuparvovec-tneq), Patent No. 10,898,585 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2025-E-0369

Patent Term Application for KEBILIDI® (eladocagene exuparvovec-tneq), Patent No. 10,898,585

Documents

Comments

Description

OPEN

Comment Period OpensFeb 4, 2025

Comment Period ClosesApr 15, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI FR Doc: 2026-02976	Feb 13, 2026	--

CDER

Patent Term Application for KEBILIDI®

Polsinelli PC

National Taiwan University

(eladocagene exuparvovec-tneq)

Patent No. 10,898,585

OPEN